How Much Does Foundayo (Orforglipron) Cost in 2026?
Foundayo monthly cost by payment channel
| Channel | Monthly cost |
|---|---|
| Commercial insurance + savings program | $25 |
| Insurance copay only (no savings program) | $25 to $100 |
| Medicare Part D (from July 1, 2026) | $50 |
| LillyDirect self-pay (lowest dose) | $149 |
| LillyDirect self-pay (higher doses) | $299 |
| LillyDirect self-pay (14.5 / 17.2 mg out of window) | $349 |
| Retail / telehealth pricing | Varies |
| Cash retail (full WAC) | $1,099 |
Foundayo vs every other GLP-1: cost and efficacy head-to-head
| Drug | Form | Cheapest cash-pay | Trial weight loss |
|---|---|---|---|
| Foundayo (orforglipron) | Daily oral, no restrictions | $149/mo (LillyDirect) | 14.7% (ATTAIN-1, 72 wk) |
| Wegovy oral 25 mg | Daily oral, empty stomach | $149/mo (NovoCare) | 13.6% (OASIS-4, 68 wk) |
| Wegovy injection | Weekly injection | $349/mo (NovoCare) | 14.9% (STEP-1, 68 wk) |
| Zepbound | Weekly injection | $299/mo starter (LillyDirect) | 22.5% (SURMOUNT-1, 72 wk) |
At the lowest dose, Foundayo and oral Wegovy 25 mg are tied as the cheapest branded FDA-approved GLP-1 cash-pay paths in the US in 2026, both at $149/month via their respective manufacturer programs. Foundayo's advantage over oral Wegovy is no fasting requirement. Zepbound remains the efficacy leader by a wide margin but at higher cost and requires weekly injection.
The April 1, 2026 approval in context
Foundayo (orforglipron) is the fifth FDA approval under the Commissioner's National Priority Voucher (CNPV) pilot program and the first new molecular entity (NME) cleared under it. The CNPV compressed review timeline let Eli Lilly pre-manufacture roughly $1.5 billion in supply ahead of approval. As a result, first shipments via LillyDirect started on April 6, 2026 (five days after approval), and broader retail and telehealth availability (CVS, Walgreens, Ro) launched April 9, 2026. Foundayo is the first GLP-1 receptor agonist that is a non-peptide small molecule, which is why it does not require fasting or strict water restrictions like oral Wegovy 25 mg.
Foundayo (orforglipron) coverage by major insurer
Coverage stance and per-carrier details for Foundayo (orforglipron). Each link goes to the full prior-auth requirements, cost table, and appeal playbook for that carrier.
Frequently asked questions
How much does Foundayo cost per month in 2026?
$149/month through LillyDirect for the lowest dose, up to $299/month for higher doses within the 45-day refill window. Standard pricing for the highest doses (14.5 mg and 17.2 mg) is $349/month if you do not refill within 45 days. With commercial insurance: as low as $25/month if your plan covers Foundayo. Medicare Part D enrollees may pay as low as $50/month beginning July 1, 2026. List price (WAC) is approximately $1,099/month - almost no one pays this. Foundayo was FDA-approved April 1, 2026 and started shipping via LillyDirect on April 6, 2026.
Is Foundayo cheaper than Wegovy or Zepbound?
At LillyDirect self-pay, Foundayo starts at $149/month for the lowest dose, the same starting point as oral Wegovy 25 mg ($149/month at NovoCare for 1.5 / 4 mg). For comparison: Wegovy injection is $349/month at NovoCare standard ongoing, and Zepbound starts at $299/month for the 2.5 mg starter vial at LillyDirect (rising to $399 / $449 at higher doses). So at the lowest dose, Foundayo and oral Wegovy are tied as the cheapest branded GLP-1 cash-pay paths in the US in 2026. At higher Foundayo doses ($299-$349/month) it converges with Zepbound and undercuts Wegovy injection.
What is the National Priority Voucher Program and why does it matter for Foundayo pricing?
The Commissioner's National Priority Voucher (CNPV) is an FDA pilot program that compresses NDA review timelines for drugs addressing priority public health areas. Foundayo (orforglipron) was the fifth approval under this program and the first new molecular entity (NME) cleared under it. Eli Lilly received an accelerated review relative to the original PDUFA date, allowing the April 1, 2026 approval. The faster timeline let Lilly pre-manufacture roughly $1.5 billion in supply ahead of approval, which is why first shipments started just five days after approval (April 6 via LillyDirect, April 9 via retail and telehealth partners CVS, Walgreens, Ro). Aggressive supply enabled aggressive launch pricing at $149/month for the lowest dose.
How is Foundayo different from oral Wegovy 25 mg?
Three big differences. (1) Foundayo is a non-peptide small molecule; oral Wegovy 25 mg is a peptide tablet. That difference is the reason for the second point. (2) NO food or water restrictions for Foundayo: take it any time of day, with or without food, with any amount of water. Oral Wegovy 25 mg requires fasting (max 4 oz water in the morning, then a 30-minute fast before food or other oral meds), which is the single biggest adherence barrier for that drug. (3) Efficacy: Foundayo reached 14.7% mean weight loss in ATTAIN-1 over 72 weeks; oral Wegovy reached 13.6% in OASIS-4 over 68 weeks. Similar headline efficacy, but the dosing flexibility is the practical difference most patients will feel day-to-day.
How is Foundayo different from Wegovy or Zepbound injections?
Form factor and efficacy. Foundayo is a daily pill (no injections, no fridge storage, easy to travel with); Wegovy and Zepbound are weekly subcutaneous injections. Efficacy ranking from clinical trials: Zepbound 22.5% (SURMOUNT-1, 72 weeks) > Wegovy injection 14.9% (STEP-1, 68 weeks) > Foundayo 14.7% (ATTAIN-1, 72 weeks). So Foundayo is competitive with Wegovy injection on efficacy but trails Zepbound by roughly 8 percentage points. Trade-off: you give up roughly 8 points of expected weight loss versus Zepbound in exchange for no needles and no weekly storage logistics. For many patients that's worth it.
Where can I buy Foundayo?
Three channels as of May 2026. (1) LillyDirect (lilly.com/lillydirect/medicines/foundayo) - the official manufacturer direct-to-consumer channel, shipping since April 6, 2026. This is the cheapest cash-pay path at $149/month for the lowest dose. (2) Retail pharmacies (CVS, Walgreens, and other major chains) - available since April 9, 2026 with a prescription. Use this if you have insurance that covers Foundayo and a copay structure that beats the LillyDirect cash price. (3) Telehealth platforms including Ro, with broader telehealth rollout in progress through Q2 2026. Telehealth adds a prescriber-visit fee on top of drug acquisition cost.
Does insurance cover Foundayo?
Coverage is rolling out gradually since the April 2026 approval. Major commercial insurers typically add new GLP-1s to their formularies on a quarterly review cycle. Expect formulary inclusion at most large commercial insurers (Aetna, Cigna, UnitedHealthcare, Anthem BCBS) through Q3 2026, often with prior authorization requirements similar to Wegovy and Zepbound (documented BMI threshold, prior weight-loss attempts, sometimes provider counseling). If covered, expect $25 to $100/month copay plus the manufacturer savings program where eligible. Government insurance (traditional Medicare, Medicaid, VA, Tricare) is excluded from manufacturer savings cards by federal anti-kickback statute, same as every other GLP-1.
Does Medicare cover Foundayo?
Medicare Part D coverage starts July 1, 2026 with eligible patients paying as low as $50/month per Eli Lilly's announced terms. The same statutory exclusion that affects Wegovy injection applies in principle (the Medicare Modernization Act of 2003 excludes drugs prescribed solely for weight loss from Part D), but Lilly has structured pricing terms that include Medicare-eligible patients at the $50/month tier. Traditional Medicare beneficiaries should verify with their Part D plan after July 1; Medicare Advantage plans vary plan-to-plan. Medicaid coverage is determined state-by-state.
What are the side effects?
Same GI side effect profile as other GLP-1s. Most-reported in ATTAIN-1: nausea, diarrhea, vomiting, and constipation. Severity is typically mild to moderate, concentrated during the dose-escalation period (first 4 to 8 weeks). Because Foundayo is a small molecule and not a peptide, it does not require the strict fasting schedule that drives some of the GI tolerability issues with oral Wegovy 25 mg. See our /side-effects/orforglipron page for the per-side-effect timing, severity, and management protocol.
Will Foundayo get cheaper over time?
Likely yes. Three competitive pressures are forming. (1) Novo Nordisk is expected to respond with a comparable oral semaglutide subscription or LillyDirect-equivalent program, similar to the Wegovy subscription program launched in March 2026. (2) Other oral GLP-1s in late-stage development (Pfizer's danuglipron program restart, etc.) will add to the competitive set. (3) Lilly's own price strategy depends on volume targets - if uptake is strong, expect higher-dose pricing tiers to compress over time. Subscribe below to get an email when LillyDirect or NovoCare adjusts Foundayo or oral semaglutide pricing.
Related guides
Track Foundayo (orforglipron) pricing and availability
Eli Lilly's daily oral pill Foundayo (orforglipron) was FDA-approved April 1, 2026 and starts at $149/mo via LillyDirect. We'll email you when pricing tiers change, insurance coverage expands, or new head-to-head data lands vs. Wegovy and Zepbound.